Some retrospective data and randomized trials have shown that the severe skin reactions caused by anti-EGFR antagonists correlate with overall survival (OS) and progression-free survival (PFS), but the result is still controversial [15,16,17]. The gene discussed is EGFR; the disease is skin reaction.